Real‑world effectiveness of venetoclax‑rituximab in relapsed or refractory chronic lymphocytic leukemia in Belgium: results from the AREVEDECY study
Year: 2026
Type: article
Abstract: Outcomes from the Phase 3 MURANO trial support the efficacy of a two‑year regimen of venetoclax + rituximab (VenR) in relapsed/refractory chronic lymphocytic leukemia (R/R CLL). To evaluate outcomes with the Belgian reimbursed VenR treatment strategy in routine clinical practice, we conducted a retrospective chart review of adults with R/R CLL prescribed VenR at nine clinical centers in Belgium. Data were collected from September 2019 until site‑specific ethical approval (October 2022–February 2023). 117 patients were included in the VenR-intended cohort, with records observed for a mean 19.2 (standard deviation, 10.5) months. At index, mean age was 71 years; 45% of patients had prior Bruton tyrosine kinase inhibitor (BTKi) exposure. Overall response rate was 90% among patients with an available response assessment. At 24 months, estimated overall survival (OS) was 80.8% (95% confidence interval [CI], 72.8%–89.6%), progression-free survival (PFS) was 77.5% (95% CI, 69.1%–87.0%). 82 patients (70%) received ≥ 1 rituximab administration; 35 (30%) did not, most commonly (71%) due to COVID-19-related circumstances; 24-month OS and PFS were lower in patients not receiving rituximab (OS: 69.3% vs. 85.7%; PFS: 69.6% vs. 80.8%). BTKi-experienced patients had numerically lower 24-month OS (75.5% vs. 84.7%) and PFS (70.0% vs. 83.2%) than BTKi-naïve patients. Treatment discontinuations occurred in 39% of patients, and dose reductions in 29%. Mean daily venetoclax dose was 328.5 mg. Overall, real-world outcomes with the Belgian reimbursed VenR treatment strategy were broadly consistent with MURANO trial outcomes, despite substantial proportions of this sample having BTKi experience or never receiving rituximab.
Source: Annals of Hematology
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,590
OpenAlex ID: W7237344768
FWCI:
Cites:
Cited by:
Related to:
